Varaico: Literature-Extracted Genetic Variants

Gene:PIK3CA
Variant:p.L285*
Back to variants list

PIK3CA

NM_006218.4:p.L285*

Associated Papers

The Prevalence, Distribution, and Clinicopathological Features of Seven Lung Cancer Actionable Driver Mutations in Taiwan.

Lin YC et al.

Thoracic Cancer, 2025

Systematic evaluation of clinical efficacy of CYP1B1 gene polymorphism in EGFR mutant non-small cell lung cancer observed by medical image.

Zhang S et al.

Open Life Sciences, 2023

Genomic Alteration Spectrum of Non-Small Cell Lung Cancer Patients in East-China Characterized by Tumor Tissue DNA and Cell-Free DNA.

Li J et al.

Oncotargets and Therapy, 2022

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.

Karlsen EA et al.

Cells, 2021

Outgrowth of erlotinib-resistant subpopulations recapitulated in patient-derived lung tumor spheroids and organoids.

Banda M et al.

Plos One, 2020

Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.

Grosse A et al.

Diagnostic Pathology, 2019

Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome.

Grosse C et al.

Plos One, 2019

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.

Stewart EL et al.

Translational Lung Cancer Research, 2015

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.

Yeh P et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013

EGFR mutations and the terminal respiratory unit.

Yatabe Y

Cancer Metastasis Reviews, 2010

Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment.

Portet S et al.

Neuro-oncology Advances, 0

32642646 (PubMed )
Supplement: vdz003_suppl_supplementary_table_1.xlsx › Feuil1
Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."